CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
BIA 2-093 +2 moredrug
Likely dose
BIA 2-093 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02279667
NCT02279667Phase 1Completed
CompareCT.gov

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093 in Healthy Volunteers

Bial - Portela C S.A.·interventional·Posted Oct 31, 2014·Updated Jan 1, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 2-093 for Epilepsy. Completed, enrolled 18 participants across 1 site.

Detailed Summary

Single centre, open-label, randomised, three-way crossover study in 18 healthy subjects (9 males and 9 females). The study consisted of three consecutive single-dose treatment periods separated by a washout period of 7 days or more. On each treatment period, the volunteers received a single dose of BIA 2-093 800 mg, orally.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesPortugal
Collaborators--

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 31, 2014
Enrollment StartFeb 1, 2004
Primary CompletionMar 1, 2004
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.7 years ago

Interventions

BIA 2-093drug

oral suspension 50 mg/mL

BIA 2-093drug

200 mg tablet

BIA 2-093drug

800 mg tablet